サノフィ株式会社

ディレグラ配合錠

[redacted]申請資料の目次

Total number of pages: 9

[redacted] 目 次

[redacted]

[redacted]申請資料の目次
ディレグラ配合錠

[redacted]

[redacted]申請資料の目次
ディレグラ配合錠

[redacted]
[redacted]
[redacted]
[redacted]
[redacted]
[redacted]
[redacted]
[redacted]
[redacted]
[redacted]

第 二 部 目 次

2.2 緒言
2.3 品質に関する概括資料
2.3 緒言
2.3.S 原薬 （塩酸プソイドエフェドリン）
2.3.P 製造（ディレグラ配合錠、錠剤）
2.3.A その他
2.4 非臨床試験の概括評価
2.5 臨床に関する概括評価
2.6 非臨床試験の概要文及び概要表
2.6.1 緒言
2.6.2 薬理試験の概要文
2.6.3 薬理試験概要表
2.6.4 薬物動態試験の概要文
2.6.5 薬物動態試験概要表
2.6.6 毒性試験の概要文
2.6.7 毒性試験概要表
2.7 臨床概要
2.7.1 生物薬剤学及び関連する分析法の概要
2.7.2 臨床薬理の概要
2.7.3 臨床的有効性の概要
2.7.4 臨床的安全性の概要
2.7.5 参考文献
2.7.6 個々の試験のまとめ

第 三 部 目 次

3.2.S 原薬 （塩酸プソイドエフェドリン）
3.2.S.1 General Information
3.2.S.1.1 Nomenclature
3.2.S.1.2 Structure
3.2.S.2 Manufacture
3.2.S.2.1 Manufacturer
3.2.S.2.2 Description of Manufacturing Process and Process Controls
3.2.S.2.3 Control of Materials
3.2.S.2.4 Controls of Critical Steps and Intermediates
3.2.S.2.6 Manufacturing Process Development
3.2.S.6 Container Closure Systems
3.2.P 製剤 （ディレグラ配合錠, 錠剤）
3.2.P.1 Description and Composition of the Drug Product
3.2.P.2 Pharmaceutical Development
3.2.P.2.1 Components of the drug product
3.2.P.2.2 Drug product
3.2.P.2.3 Manufacturing process development
3.2.P.2.4 Container closure system
3.2.P.2.5 Microbiological attributes
3.2.P.2.6 Compatibility
3.2.P.3 Manufacture
3.2.P.3.1 Manufacturer(s)
3.2.P.3.2 Batch Formula
3.2.P.3.3 Description of Manufacturing Process and Process Controls
3.2.P.3.4 Controls of Critical Steps and Intermediates
3.2.P.3.5 Process Validation and/or Evaluation
3.2.P.4 Control of Excipients (compendial)
3.2.P.4.1 Specification
3.2.P.4.2 Analytical procedures
3.2.P.4.3 Validation of Analytical Procedures
3.2.P.4.4 Justification of specifications
3.2.P.4 Control of Excipients (Carnauba wax)

3.2.P.4.1 Specification
3.2.P.4.2 Analytical procedures
3.2.P.4.3 Validation of Analytical Procedures
3.2.P.4.4 Justification of specifications
3.2.P.4 Control of Excipients (animal-human-novel)
3.2.P.4.5 Excipients of human or animal origin
3.2.P.4.6 Novel Excipients
3.2.P.5 Control of Drug Product
3.2.P.5.1 Specification
3.2.P.5.2 Analytical procedures
3.2.P.5.3 Validation of Analytical Procedures
3.2.P.5.4 Batch analyses
3.2.P.5.5 Characterization of impurities
3.2.P.5.6 Justification of Specification
3.2.P.6 Reference standards or materials
3.2.P.7 Container Closure System
3.2.P.8 Stability
3.2.P.8.1 Stability Summary and Conclusion
3.2.P.8.2 Registration post-approval stability protocol and stability commitment
3.2.P.8.3 Stability Data
3.2.A Appendices
3.2.A.1 Facilities and Equipment
3.2.A.2 Adventitious Agents Safety Evaluation
3.2.A.3 Excipients

第 四 部 目 次

4 Nonclinical Study Reports
4.2 Study Reports
4.2.2 Pharmacokinetics
4.2.2.1 Analytical Methods and Validation Reports
4.2.2.1-1 Validation of a high performance liquid chromatographic method using tandem mass spectrometry detection for the determination of fexofenadine in human EDTA K3 plasma
4.2.2.1-2 Validation of a high performance liquid chromatographic method using tandem mass spectrometry detection and automated extraction for the determination of pseudoephedrine in human EDTA plasma
4.2.3 Toxicology
4.2.3.1 Single Dose Toxicity
4.2.3.1-1 The effect of terfenadine on the acute oral toxicity of pseudoephedrine hydrochloride in rats
4.2.3.1-2 Determination of comparative oral minumum lethal dose of a sustained release form of d-pseudoephedrine versus the raw form of d-pseudoephedrine in the dog
4.2.3.1-3 Determination of comparative oral minumum lethal dose of sustained release capsule versus immediate release cupsule of d-pseudoephedrine
4.2.3.2 Repeat Dose Toxicity
4.2.3.2-1 Range finding study with a terfenadine/pseudoephedrine hydrochloride combination in rats
4.2.3.2-2 Three month oral toxicity study of a terfenadine/pseudoephedrine hydrochloride combination in rats
4.2.3.2-3 Subacute (30-day) oral toxicity of novafed 120 in New Zealand white rabbits
4.2.3.2-4 Subacute (30-day) oral toxicity of novafed 120 (d-pseudoephedrine HCl) in mongrel dogs
4.2.3.2-5 Subacute (39-day) oral toxicity of novafed 120 (d-pseudoephedrine HCL) in beagle dog
4.2.3.2-6 Three month oral toxicity of a terfenadine/pseudoephedrine hydrochloride in dogs
4.2.3.5 Reproductive and Developmental Toxicity
4.2.3.5.2 Embryofetal development
4.2.3.5.2-1 Teratology study with a terfenadine/pseudoephedrine hydrochloride combination in rats
4.2.3.5.2-2 Teratology study with a combination of terfenadine/pseudoephedrine hydrochloride combination in rabbits
4.3 Literature References

第 五 部 目 次

5 Clinical Study Reports
5.2 Tabular Listing of All Clinical Studies
5.3 Clinical study reports and related information
5.3.1 Reports of Biopharmaceutic Studies
5.3.1.2 Comparative BA and Bioequivalence (BE) Study Reports
5.3.1.2-1 A double-blind, randomized, 5-day repeated-dose, dose ascending, crossover bioavailability, safety and tolerability study of fexofenadine and pseudoephedrine fixed-dose combination tablet in comparison with the marketed Allegra tablet in Japanese healthy male subjects
5.3.3 Reports of Human Pharmacokinetic (PK) Studies
5.3.3.4 Extrinsic Factor PK Study Reports
5.3.3.4-1 An open-label, randomized, single-dose, two-treatment crossover study, to investigate the potential food effect on the bioavailability of fixed dose combination formulation of fexofenadine hydrochloride and pseudoephedrine hydrochloride in Japanese healthy male subjects
5.3.3.4-2 Effect of pseudoephedrine on the pharmacokinetics of fexofenadine
5.3.5 Reports of Efficacy and Safety Studies - allergic rhinitis
5.3.5.1 Study Reports of Controlled Clinical Studies Pertinent to the Claimed Indication
5.3.5.1-1 季節性アレルギー性鼻炎患者に対して、フェキソフェナジン塩酸塩 60 mg / 塩酸プソイドエフェドリン 60 mg 配合剤又はフェキソフェナジン塩酸塩 60 mg / 塩酸プソイドエフェドリン 120 mg 配合剤を 1 日 2 回投与したときの 2 週間の有効性及び安全性の検討（ランダム化、二重盲検、フェキソフェナジン塩酸塩 60 mg 1 日 2 回投与対照、並行群間比較試験）
5.3.5.1-2 A comparative study of the safety and efficacy of a twice-daily fexofenadine HCl 60 mg pseudoephedrine HCl 120 mg combination versus its components alone in the management of ragweed seasonal allergy
5.3.6 Reports of Postmarketing Experience
Post-Marketing Safety Information on Allegra FDC (fexofenadine / pseudoephedrine combination)
PERIODIC SAFETY UPDATE REPORT for FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HCL/PSEUDOEPHEDRINE HCL, FEXOFENADINE HCL/PHENYLEPHRINE HCL
5.3.7 CRF and individual patient listings
5.3.7-1 用量設定の根拠となった主要な試験及び主要な有効性の検証試験の症例一覧表
5.3.7-2 実施された全ての臨床試験において副作用が観察された症例の一覧表
5.3.7-4 実施された全ての臨床試験において臨床検査値異常が観察された症例の一覧表
5.4 Literature References